Dr. Jean H. Siedel
Claim this profileUniversity of Michigan Comprehensive Cancer Center
Area of expertise
Ovarian Cancer
Jean H. Siedel has run 4 trials for Ovarian Cancer. Some of their research focus areas include:
Endometrial Adenocarcinoma
Jean H. Siedel has run 4 trials for Endometrial Adenocarcinoma. Some of their research focus areas include:
Affiliated Hospitals
University Of Michigan Comprehensive Cancer Center
University Of Michigan - Brighton Center For Specialty Care
Clinical Trials Jean H. Siedel is currently running
Selumetinib + Olaparib
for Ovarian and Endometrial Cancer
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
Recruiting
1 award
Phase 2
Herceptin Hylecta or Phesgo + Chemotherapy
for Uterine Cancer
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.
Recruiting
2 awards
Phase 3
More about Jean H. Siedel
Clinical Trial Related
2 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Jean H. Siedel has experience with
- Olaparib
- Carboplatin
- Paclitaxel
- Cediranib Maleate
- Durvalumab
- Letrozole
Breakdown of trials Jean H. Siedel has run
Ovarian Cancer
Endometrial Adenocarcinoma
Fallopian Tube Cancer
Endometrial Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jean H. Siedel specialize in?
Jean H. Siedel focuses on Ovarian Cancer and Endometrial Adenocarcinoma. In particular, much of their work with Ovarian Cancer has involved Stage IV patients, or patients who are Stage II.
Is Jean H. Siedel currently recruiting for clinical trials?
Yes, Jean H. Siedel is currently recruiting for 2 clinical trials in Ann Arbor Michigan. If you're interested in participating, you should apply.
Are there any treatments that Jean H. Siedel has studied deeply?
Yes, Jean H. Siedel has studied treatments such as Olaparib, Carboplatin, Paclitaxel.
What is the best way to schedule an appointment with Jean H. Siedel?
Apply for one of the trials that Jean H. Siedel is conducting.
What is the office address of Jean H. Siedel?
The office of Jean H. Siedel is located at: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 United States. This is the address for their practice at the University of Michigan Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.